First Leqembi Alzheimer Treatment in Sweden
Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The Swedish launch of Leqembi expands commercial access for BioArctic and Eisai in the Nordic region, supporting royalty and milestone revenue expectations for BioArctic despite the lack of public reimbursement. Market reaction is likely modest and company-specific, as the event is a small geographic commercial milestone rather than a major regulatory or clinical catalyst.
BioArctic announced that Leqembi (lecanemab), the first therapy targeting an underlying cause of Alzheimer's disease, is now available at a private clinic in Sweden and that the first patient has started treatment. This marks the first time a patient in Sweden has been treated outside of a clinical study since Leqembi received EU approval in April 2025. The treatment was administered at Executive Health in Stockholm, which worked to offer the therapy after the New Therapies Council (NT-radet) in April 2026 gave a negative recommendation for including Leqembi in the publicly funded health care system. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, originally developed by BioArctic based on research by Professor Lars Lannfelt at Uppsala University on the Arctic mutation. Eisai handles clinical development, regulatory applications and global commercialization, while BioArctic holds commercialization rights in the Nordic region together with Eisai. Leqembi is approved in 53 countries and under regulatory review in 6, with subcutaneous initiation treatment approved in China and Japan in September 2026. BioArctic CEO Gunilla Osswald highlighted the significant unmet need for treatments that slow early Alzheimer's progression. Ongoing studies include Eisai's Phase 3 AHEAD 3-45 trial, a public-private partnership with Biogen and the Alzheimer's Clinical Trial Consortium funded by the National Institute on Aging, part of the United States — National Institutes of Health, and the Tau NexGen study led by Washington University in St. Louis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard